{"id":"4e77126c7400","type":"article","url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","title":"Nieuwe medicamenteuze therapieën voor hypertensie","title_en":"New drug therapies for hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["baxdrostat","bloeddrukbehandeling","lorundrostat","ras-remmers","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02064-1/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02064-1/fulltext","authors":["Michel Azizi","Katherine R Tuttle","Jenifer M Brown","Daniel L Piskorz","Kazuomi Kario","Bryan Williams"],"significance":8,"published":"2026-03-14","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/"],"congress":"","summary_en":"This Lancet review described new drug therapies for hypertension targeting novel physiological pathways including aldosterone synthase inhibition, endothelin antagonism, and RNA interference-based angiotensinogen silencing, addressing the unmet need for patients with resistant blood pressure.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit Lancet-overzichtsartikel bespreekt innovatieve antihypertensiva die aangrijpen op andere fysiologische routes dan de huidige medicatieklassen. Behandeld worden onder meer small interfering RNA-middelen en andere nieuwe benaderingen die de bloeddrukbehandeling kunnen verbeteren bij patiënten met therapie-ontrouw of resistente hypertensie.","abstract_original":"Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic inertia, and rising multimorbidity, underscore the need for innovative approaches to improve hypertension care. New antihypertensive drug therapies that act on physiological pathways beyond those targeted by conventional drug classes are emerging. These therapies include small interfering RNA agents that inhibit angiotensinogen synthesis as a novel approach to inhibit the renin–angiotensin system, and new strategies to more selectively modulate aldosterone, such as aldosterone synthase inhibitors and non-steroidal mineralocorticoid receptor antagonists."}